Below is an overview of how the two compare: Mechanism of Action: Retatrutide: Triple agonist (GLP-1, GIP, glucagon) Zepbound: Dual agonist (GLP-1, GIP) Developer: Retatrutide: Eli Lilly and Company (investigational) Zepbound: Eli Lilly and Company (approved) Regulatory Status: Retatrutide: Phase III clinical development Zepbound: FDA-approved for obesity, obstructive sleep apnea Weight Loss Efficacy: Retatrutide: Up to ~28.7% (68 weeks
Rare reports of pulmonary aspiration have occurred in people using GLP-1 medications during procedures requiring general anesthesia or deep sedation, even when fasting instructions were reportedly followed
All peptides are shipped in secure packaging for the transit across Canada
The formula also includes ginger, known for its stomach-soothing effects, and peppermint, which can help relax digestive muscles and reduce spasms that contribute to bloating
Important examples are detailed below
While the effects of Semaglutide GLP-1 can vary depending on individual factors like initial weight and adherence to therapy, the overall medical evidence strongly suggests that it can be effective for significant and sustained weight loss
